Literature DB >> 22383253

The carmaphycins: new proteasome inhibitors exhibiting an α,β-epoxyketone warhead from a marine cyanobacterium.

Alban R Pereira1, Andrew J Kale, Andrew T Fenley, Tara Byrum, Hosana M Debonsi, Michael K Gilson, Frederick A Valeriote, Bradley S Moore, William H Gerwick.   

Abstract

Two new peptidic proteasome inhibitors were isolated as trace components from a Curaçao collection of the marine cyanobacterium Symploca sp. Carmaphycin A (1) and carmaphycin B (2) feature a leucine-derived α,β-epoxyketone warhead directly connected to either methionine sulfoxide or methionine sulfone. Their structures were elucidated on the basis of extensive NMR and MS analyses and confirmed by total synthesis, which in turn provided more material for further biological evaluations. Pure carmaphycins A and B were found to inhibit the β5 subunit (chymotrypsin-like activity) of the S. cerevisiae 20S proteasome in the low nanomolar range. Additionally, they exhibited strong cytotoxicity to lung and colon cancer cell lines, as well as exquisite antiproliferative effects in the NCI60 cell-line panel. These assay results as well as initial structural biology studies suggest a distinctive binding mode for these new inhibitors.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22383253      PMCID: PMC3393770          DOI: 10.1002/cbic.201200007

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  34 in total

1.  Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor.

Authors:  M Groll; Y Koguchi; R Huber; J Kohno
Journal:  J Mol Biol       Date:  2001-08-17       Impact factor: 5.469

2.  A functional genomics approach to the mode of action of apratoxin A.

Authors:  Hendrik Luesch; Sumit K Chanda; R Marina Raya; Paul D DeJesus; Anthony P Orth; John R Walker; Juan Carlos Izpisúa Belmonte; Peter G Schultz
Journal:  Nat Chem Biol       Date:  2006-02-12       Impact factor: 15.040

3.  Epopromycins, novel cell wall synthesis inhibitors of plant protoplast produced by Streptomyces sp. NK04000.

Authors:  K Tsuchiya; S Kobayashi; T Nishikiori; T Nakagawa; K Tatsuta
Journal:  J Antibiot (Tokyo)       Date:  1997-03       Impact factor: 2.649

4.  Two cytotoxic stereoisomers of malyngamide C, 8-epi-malyngamide C and 8-O-acetyl-8-epi-malyngamide C, from the marine cyanobacterium Lyngbya majuscula.

Authors:  Harald Gross; Kerry L McPhail; Douglas E Goeger; Frederick A Valeriote; William H Gerwick
Journal:  Phytochemistry       Date:  2010-08-09       Impact factor: 4.072

5.  Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding.

Authors:  Michael Groll; Robert Huber; Barbara C M Potts
Journal:  J Am Chem Soc       Date:  2006-04-19       Impact factor: 15.419

Review 6.  Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Authors:  B C Potts; M X Albitar; K C Anderson; S Baritaki; C Berkers; B Bonavida; J Chandra; D Chauhan; J C Cusack; W Fenical; I M Ghobrial; M Groll; P R Jensen; K S Lam; G K Lloyd; W McBride; D J McConkey; C P Miller; S T C Neuteboom; Y Oki; H Ovaa; F Pajonk; P G Richardson; A M Roccaro; C M Sloss; M A Spear; E Valashi; A Younes; M A Palladino
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

Review 7.  Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds.

Authors:  Alejandro M S Mayer; Kirk R Gustafson
Journal:  Eur J Cancer       Date:  2008-08-11       Impact factor: 9.162

Review 8.  The potential of proteasome inhibitors in cancer therapy.

Authors:  Jan Sterz; Ivana von Metzler; Jens-Claus Hahne; Britta Lamottke; Jessica Rademacher; Ulrike Heider; Evangelos Terpos; Orhan Sezer
Journal:  Expert Opin Investig Drugs       Date:  2008-06       Impact factor: 6.206

9.  Epoxomicin, a new antitumor agent of microbial origin.

Authors:  M Hanada; K Sugawara; K Kaneta; S Toda; Y Nishiyama; K Tomita; H Yamamoto; M Konishi; T Oki
Journal:  J Antibiot (Tokyo)       Date:  1992-11       Impact factor: 2.649

10.  Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica.

Authors:  Markus Nett; Tobias A M Gulder; Andrew J Kale; Chambers C Hughes; Bradley S Moore
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

View more
  35 in total

1.  Molecular networking as a dereplication strategy.

Authors:  Jane Y Yang; Laura M Sanchez; Christopher M Rath; Xueting Liu; Paul D Boudreau; Nicole Bruns; Evgenia Glukhov; Anne Wodtke; Rafael de Felicio; Amanda Fenner; Weng Ruh Wong; Roger G Linington; Lixin Zhang; Hosana M Debonsi; William H Gerwick; Pieter C Dorrestein
Journal:  J Nat Prod       Date:  2013-09-11       Impact factor: 4.050

Review 2.  Biological targets and mechanisms of action of natural products from marine cyanobacteria.

Authors:  Lilibeth A Salvador-Reyes; Hendrik Luesch
Journal:  Nat Prod Rep       Date:  2015-03       Impact factor: 13.423

Review 3.  Advances in exploring the therapeutic potential of marine natural products.

Authors:  Xiao Liang; Danmeng Luo; Hendrik Luesch
Journal:  Pharmacol Res       Date:  2019-07-25       Impact factor: 7.658

4.  A Maldiisotopic Approach to Discover Natural Products: Cryptomaldamide, a Hybrid Tripeptide from the Marine Cyanobacterium Moorea producens.

Authors:  Robin B Kinnel; Eduardo Esquenazi; Tiago Leao; Nathan Moss; Emily Mevers; Alban R Pereira; Emily A Monroe; Anton Korobeynikov; Thomas F Murray; David Sherman; Lena Gerwick; Pieter C Dorrestein; William H Gerwick
Journal:  J Nat Prod       Date:  2017-04-27       Impact factor: 4.050

5.  Identifying the Minimal Enzymes Required for Biosynthesis of Epoxyketone Proteasome Inhibitors.

Authors:  Joyce Liu; Xuejun Zhu; Wenjun Zhang
Journal:  Chembiochem       Date:  2015-11-02       Impact factor: 3.164

6.  The Proteasome as a Drug Target in the Metazoan Pathogen, Schistosoma mansoni.

Authors:  Betsaida Bibo-Verdugo; Steven C Wang; Jehad Almaliti; Anh P Ta; Zhenze Jiang; Derek A Wong; Christopher B Lietz; Brian M Suzuki; Nelly El-Sakkary; Vivian Hook; Guy S Salvesen; William H Gerwick; Conor R Caffrey; Anthony J O'Donoghue
Journal:  ACS Infect Dis       Date:  2019-08-12       Impact factor: 5.084

7.  20S Proteasome as a Drug Target in Trichomonas vaginalis.

Authors:  Anthony J O'Donoghue; Betsaida Bibo-Verdugo; Yukiko Miyamoto; Steven C Wang; Justin Z Yang; Douglas E Zuill; Shoun Matsuka; Zhenze Jiang; Jehad Almaliti; Conor R Caffrey; William H Gerwick; Lars Eckmann
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

8.  Roseltide rT7 is a disulfide-rich, anionic, and cell-penetrating peptide that inhibits proteasomal degradation.

Authors:  Antony Kam; Shining Loo; Jing-Song Fan; Siu Kwan Sze; Daiwen Yang; James P Tam
Journal:  J Biol Chem       Date:  2019-11-14       Impact factor: 5.157

9.  Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor.

Authors:  Daniela B B Trivella; Alban R Pereira; Martin L Stein; Yusuke Kasai; Tara Byrum; Frederick A Valeriote; Dean J Tantillo; Michael Groll; William H Gerwick; Bradley S Moore
Journal:  Chem Biol       Date:  2014-06-12

10.  The marine cyanobacterial metabolite gallinamide A is a potent and selective inhibitor of human cathepsin L.

Authors:  Bailey Miller; Aaron J Friedman; Hyukjae Choi; James Hogan; J Andrew McCammon; Vivian Hook; William H Gerwick
Journal:  J Nat Prod       Date:  2013-12-23       Impact factor: 4.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.